HomeAI · summaries
Storia in 2 fonti
ASCO 2026: key readouts in lung cancer - Pharmaceutical Technology
At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various subtypes of NSCLC.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions
- ·
pharmaceutical-technology.com
ASCO 2026: key readouts in lung cancer - Pharmaceutical Technology
At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various subtypes of NSCLC.
- ·
ASCO26: Cancer vaccines and at-home injectable drugs continue to show promise
A number of companies presented new data on their cancer vaccine candidates at ASCO 2026.